Comparative Pharmacology
Head-to-head clinical analysis: DEFERASIROX versus EXJADE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFERASIROX versus EXJADE.
DEFERASIROX vs EXJADE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces. It reduces iron burden in transfusion-dependent patients.
Deferasirox is an oral iron chelator that binds iron with high affinity in a 2:1 ratio. It promotes excretion of iron primarily in the feces via bile, reducing total body iron stores.
Initial: 20 mg/kg orally once daily. Maintenance: 20-40 mg/kg orally once daily (maximum 40 mg/kg/day).
20-40 mg/kg orally once daily, titrated based on serum ferritin trends, maximum 40 mg/kg per day.
None Documented
None Documented
Terminal elimination half-life is 8–16 hours in patients with transfusional iron overload; higher iron burden prolongs half-life due to enterohepatic recirculation.
Clinical Note
moderateDeferasirox + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateDeferasirox + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox."
Clinical Note
moderateCarprofen + Deferasirox
Terminal elimination half-life is 8–16 hours, supporting once-daily dosing.
Primarily fecal (84%) as unchanged drug via biliary excretion; renal excretion accounts for approximately 8% as unchanged drug and metabolites.
Primarily fecal (84% of total clearance), with ~8% renal (as unchanged drug and metabolites).
Category C
Category C
Iron Chelator
Iron Chelator
"The risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox."